Pulmonary hypertension classification
|
Pulmonary Hypertension Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Pulmonary hypertension classification On the Web |
|
American Roentgen Ray Society Images of Pulmonary hypertension classification |
|
Risk calculators and risk factors for Pulmonary hypertension classification |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1], Richard Channick, M.D.; Assistant Editor(s)-in-Chief: Ralph Matar; Lisa Prior, Ann Slater, R.N.; Rim Halaby, M.D. [2]
Overview
Pulmonary hypertension (PH) has been previously classified as primary (currently known as idiopathic pulmonary arterial hypertension or IPAH) and secondary in 1973.[1] In 1988, a clinical classification of PH into 5 groups has been developed during the 2nd World Symposium on Pulmonary Hypertension in Evian, France.[2] The clinical classification has been updated regularly as the understanding of PH expanded; nevertheless, the main scheme of classification into the 5 main groups remained intact. The classification of PH has been last modified in 2013 during the 5th World Symposium on Pulmonary Hypertension in Nice, France.[3] The main 5 groups of PH include pulmonary arterial hypertension (Group 1), pulmonary hypertension due to left heart disease (Group 2), pulmonary hypertension due to chronic lung disease and/or hypoxia (Group 3), chronic thromboembolic pulmonary hypertension (Group 4), and pulmonary hypertension due to unclear multifactorial mechanisms (Group 5).[3]
Classification
Clinical Classification
PH was first classified into primary and secondary in 1973 during the World Health Organization (WHO) meeting on PH in Geneva, Switzerland.[1]
The 2-group classification of PH was replaced by a clinical 5-group classification in the 2nd World Symposium on Pulmonary Hypertension in 1998 in Evian, France.[4] Since then, the clinical classification of PH was updated in the following meetings:
- The 3d World Symposium on Pulmonary Hypertension (2003) in Venice, Italy[5]
- The 4th World Symposium on Pulmonary Hypertension (2008) in Dana Point, California, USA[6]
- The 5th World Symposium on Pulmonary Hypertension (2013) in Nice, France[3]
The updated clinical classification has been adopted by the Guidelines Committee of the European Society of Cardiology (ESC), European Respiratory Society (ERS), and International Society of Heart and Lung Transplantation (ISHLT). It is currently used by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the labeling of new drugs approved for the treatment of PH.
Shown below is a table summarizing the updated clinical classification of PH.[3]
| Group 1. Pulmonary arterial hypertension (PAH) | |
| 1.1. Idiopathic PAH | |
| 1.2. Heritable PAH 1.2.1 BMPR2 | |
| 1.3 Drug and toxin induced Definite (an epidemic or large multicenter epidemiological studies demonstrating an association between a drug and PAH) Likely (a single case-control study demonstrating an association or a multiple-case series) Possible (drugs with similar mechanisms of action as those in the definite or likely category but which have not yet been studied)
Unlikely (one in which a drug has been studied in epidemiological studies and an association with PAH has not been demonstrated) | |
| 1.4 Associated with: 1.4.1 Connective tissue disease | |
| 1’ Pulmonary veno-occlusive disease (PVOD) and/or pulmonary capillary hemangiomatosis (PCH) | |
| 1’’ Persistent pulmonary hypertension of the newborn (PPHN) | |
| Group 2. Pulmonary hypertension due to left heart disease | |
| 2.1 Left ventricular systolic dysfunction | |
| 2.2 Left ventricular diastolic dysfunction | |
| 2.3 Valvular disease | |
| 2.4 Congenital/acquired left heart inflow/outflow tract obstruction and congenital cardiomyopathies | |
| Group 3. Pulmonary hypertension due to lung diseases and/or hypoxia | |
| 3.1 Chronic obstructive pulmonary disease | |
| 3.2 Interstitial lung disease | |
| 3.3 Other pulmonary diseases with mixed restrictive and obstructive pattern | |
| 3.4 Sleep-disordered breathing | |
| 3.5 Alveolar hypoventilation disorders | |
| 3.6 Chronic exposure to high altitude | |
| 3.7 Developmental lung diseases | |
| Group 4. Chronic thromboembolic pulmonary hypertension (CTEPH) | |
| Group 5. Pulmonary hypertension with unclear multifactorial mechanisms | |
| 5.1 Hematologic disorders: chronic hemolytic anemia, myeloproliferative disorders, splenectomy | |
| 5.2 Systemic disorders: sarcoidosis, pulmonary histiocytosis, lymphangioleiomyomatosis | |
| 5.3 Metabolic disorders: glycogen storage disease, Gaucher disease, thyroid disorders | |
| 5.4 Others: tumor obstruction, fibrosing mediastinitis, chronic renal failure, segmental PH | |
Abbreviations: BMPR, bone morphogenic protein receptor type II; CAV1, caveolin-1; ENG, endoglin; HIV, human immunodeficiency virus.
Functional Classification
References
- ↑ 1.0 1.1 Hatano S, Strasser T. Primary Pulmonary Hypertension. Report on a WHO Meeting. October 15–17, 1973, Geneva: World Health Organization, 1975.
- ↑ Rich S, Rubin LJ, Abenhail L, et al. Executive summary from the World Symposium on Primary Pulmonary Hypertension 1998, Evian, France, September 6-10, 1998. Geneva: The World Health Organization.
- ↑ 3.0 3.1 3.2 3.3 Simonneau G, Gatzoulis MA, Adatia I, Celermajer D, Denton C, Ghofrani A; et al. (2013). "Updated clinical classification of pulmonary hypertension". J Am Coll Cardiol. 62 (25 Suppl): D34–41. doi:10.1016/j.jacc.2013.10.029. PMID 24355639.
- ↑ Rich S, Rubin LJ, Abenhail L, et al. Executive summary from the World Symposium on Primary Pulmonary Hypertension 1998, Evian, France, September 6-10, 1998. Geneva: The World Health Organization.
- ↑ Simonneau G, Galiè N, Rubin LJ, Langleben D, Seeger W, Domenighetti G; et al. (2004). "Clinical classification of pulmonary hypertension". J Am Coll Cardiol. 43 (12 Suppl S): 5S–12S. doi:10.1016/j.jacc.2004.02.037. PMID 15194173.
- ↑ Simonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, Denton CP; et al. (2009). "Updated clinical classification of pulmonary hypertension". J Am Coll Cardiol. 54 (1 Suppl): S43–54. doi:10.1016/j.jacc.2009.04.012. PMID 19555858.